Neurological and neurodegenerative
Neurological conditions share urgency but not biology. AHSCT for selected relapsing MS, experimental cell implants after stroke and commercial IV infusions for ALS sit on very different evidence and risk ladders.
What the registry pattern says
Stroke Recovery has the largest MSC registry footprint in this group (45 query results; 7 recruiting in the stored snapshot). Stroke Recovery has the largest exosome footprint (11). These are query-result counts, not deduplicated patients or proof of benefit.
Check disease stage, delivery route and whether the proposed cells can plausibly reach the target compartment. A registry count cannot substitute for a condition-specific endpoint.
Condition × therapy-class snapshot
| Condition | MSC | MSC recruiting | HSCT-family | Exosomes |
|---|---|---|---|---|
| ALS | 29 | 2 | 11 | 1 |
| Alzheimer's disease | 23 | 6 | 1 | 10 |
| Multiple sclerosis | 37 | 3 | 38 | 2 |
| Neuropathy | 0 | 0 | 0 | 0 |
| Parkinsons | 19 | 1 | 3 | 5 |
| Spinal Cord Injury | 38 | 2 | 11 | 1 |
| Stroke Recovery | 45 | 7 | 14 | 11 |
Source: ClinicalTrials.gov API v2 stored snapshot. Category totals add query results and may contain overlapping studies; use condition pages for interpretation.
Interactive/editorial page by the StemCellAtlas research team. Where registry or literature counts appear, they use the dated 2026-08-29 snapshot. Browser-only tools do not send or store answers. Page generated 2026-08-29. See our editorial standards.